Those who have had their cholesterol levels tested are typically informed that there are two types of primary importance: LDL, or bad cholesterol, and HDL, which is the good kind. And while much research has determined that reducing LDL protects against heart disease and cardiovascular events, some doctors have wondered whether raising HDL actually achieves the same effects. However, earlier classes of drugs (Pfizer s Torcetrapib, most notably) designed to increase HDL failed to demonstrate any beneficial effect, and were thus abandoned.
Those who have had their cholesterol levels tested are typically informed that there are two types of primary importance: LDL, or bad cholesterol, and HDL, which is the good kind. And while much research has determined that reducing LDL protects against heart disease and cardiovascular events, some doctors have wondered whether raising HDL actually achieves the same effects. However, earlier classes of drugs (Pfizer s Torcetrapib, most notably) designed to increase HDL failed to demonstrate any beneficial effect, and were thus abandoned.